Close

VIPR2 Membrane Protein Introduction

Introduction of VIPR2

VIPR2, a seven transmembrane heterotrimeric G protein-coupled receptor, is encoded by VIPR2 gene. It has been extensively studied during the past few decades because it offers numerous possibilities for therapeutic applications. VIPR2 is in the central nervous system, in the thalamus, hippocampus, suprachiasmatic nucleus and hypothalamus. Meanwhile, studies show that VIPR2 receptors are important for many physiologic functions, including glucose homeostasis, neuroprotection, memory, gut function, modulation of the immune system and circadian function.

Basic Information of VIPR2
Protein Name Vasoactive intestinal polypeptide receptor 2
Gene Name VIPR2
Aliases VPAC2
Organism Homo sapiens (Human)
UniProt ID P41587
Transmembrane Times 7
Length (aa) 438
Sequence MRTLLPPALLTCWLLAPVNSIHPECRFHLEIQEEETKCAELLRSQTEKHKACSGVWDNITCWRPANVGETVTVPCPKVFSNFYSKAGNISKNCTSDGWSETFPDFVDACGYSDPEDESKITFYILVKAIYTLGYSVSLMSLATGSIILCLFRKLHCTRNYIHLNLFLSFILRAISVLVKDDVLYSSSGTLHCPDQPSSWVGCKLSLVFLQYCIMANFFWLLVEGLYLHTLLVAMLPPRRCFLAYLLIGWGLPTVCIGAWTAARLYLEDTGCWDTNDHSVPWWVIRIPILISIIVNFVLFISIIRILLQKLTSPDVGGNDQSQYKRLAKSTLLLIPLFGVHYMVFAVFPISISSKYQILFELCLGSFQGLVVAVLYCFLNSEVQCELKRKWRSRCPTPSASRDYRVCGSSFSRNGSEGALQFHRGSRAQSFLQTETSVI

Function of VIPR2 Membrane Protein

The VIPR2 protein-coupled receptor can bind two homologous neuropeptides with high affinity, PACAP and VIP. VIPR2 is expressed optimally on activated CD4+ T lymphocytes and monocytes. Investigators have previously alluded to an important role for VIPR2 in various diseases, such as breast cancer, schizophrenia, and several psychiatric disorders. These clinical studies demonstrate it could be a potential biomarker in the clinic.

Mechanism of VIP-augmented glucose-induced insulin secretion. Fig .1 Mechanism of VIP-augmented glucose-induced insulin secretion. (Sanlioglu, 2012)

Application of VIPR2 Membrane Protein in Literature

  1. Ago Y., et al. Pathophysiological implication of the VPAC2 receptor in psychiatric disorders. Nihon Yakurigaku Zasshi. 2018, 151(6): 249-253. PubMed ID: 29887574

    This article aims at identifying the mechanism by which overactive VPAC2 signaling may lead to schizophrenia and ASD. They describe recent advances in the genetics of schizophrenia and attempt to discuss the pathophysiological role of altered VPAC2 signaling in psychiatric disorders.

  2. Hosoda Y., et al. CFH and VIPR2 as susceptibility loci in choroidal thickness and pachychoroid disease central serous chorioretinopathy. Proc Natl Acad Sci U S A. 2018, 115(24): 6261-6266. PubMed ID: 29844195

    This article conducts a genome-wide association study on choroidal thickness in 3418 individuals followed by TaqMan assays in 2,692 subjects, and they find two susceptibility loci: CFH rs800292, an established AMD susceptibility polymorphism, and VIPR2 rs3793217.

  3. Firouzabadi S.G., et al. Copy number variants in patients with autism and additional clinical features: report of VIPR2 duplication and a novel microduplication syndrome. Mol Neurobiol. 2017, 54(9): 7019-7027. PubMed ID: 27796743

    Authors in this group analyze the Copy Number Variants in Patients with Autism, present a new evidence for VIPR2 duplication, and find VIPR2 could be a potential marker for Autism.

  4. Jin C., et al. Analysis of the association of VIPR2 polymorphisms with susceptibility to schizophrenia. Psychiatry Res. 2016, 241: 104-7. PubMed ID: 27357191

    This article focuses on investigating the association between VIPR2 polymorphisms and the risk of SCZ in male patients. These results show VIPR2 is a candidate site for SCZ therapy.

  5. Olson K.E., et al. Manganese-enhanced magnetic resonance imaging for detection of vasoactive intestinal peptide receptor 2 agonist therapy in a model of Parkinson's disease. Neurotherapeutics. 2016, 13(3): 635-46. PubMed ID: 27329163

    Authors establish manganese-enhanced magnetic resonance imaging (MEMRI) assays to track a linkage between glial activation and VIPR2 agonist (LBT-3627)-induced neuroprotective immunity for MPTP-induced nigrostriatal degeneration.

VIPR2 Preparation Options

To obtain the soluble and functional target protein, the versatile Magic™ membrane protein production platform in Creative Biolabs enables many flexible options, from which you can always find a better match for your particular project. Aided by our versatile Magic™ anti-membrane protein antibody discovery platform, we also provide customized anti-VIPR2 antibody development services.


As a forward-looking research institute as well as a leading custom service provider in the field of membrane protein, Creative Biolabs has won good reputation among our worldwide customers for successfully accomplishing numerous challenging projects including generation of many functional membrane proteins. Please feel free to contact us for more information.

Reference

  1. Sanlioglu A D, et al. (2012). Therapeutic potential of VIP vs PACAP in diabetes. J Mol Endocrinol. 49(3), R157-67.

Online Inquiry

Verification code
Click image to refresh the verification code.

CONTACT US

45-1 Ramsey Road, Shirley, NY 11967, USA
Call us at:
USA: 1-631-381-2994
Europe: 44-207-097-1828
Fax: 1-631-207-8356
Email:
Our customer service representatives are available 24 hours a day, 7 days a week. Contact Us